Drug products approved under this program are subject to the postmarketing recordkeeping and safety reporting applicable to all approved drug products, as provided in §§ 314.80 and 314.81.
Cross-references to the CFR
314.80
21 C.F.R. § 314.540: Postmarketing safety reporting. | Justis AI